AstraZeneca

AstraZeneca 3Q10

3Q Revenues: $7.9 billion (-4%)

3Q Earnings: $1.8 billion (-23%)

YTD Revenues: $24.7 billion (+3%)

YTD Earnings: $6.2 billion (-1%)

Comments: Generic competition in the U.S. for Arimidex, Pulmicort Respules and Toprol-XL, along with a lack of H1N1 pandemic vaccine revenue, led U.S. sales to drop 13% in 3Q10 to $3.2 billion. U.S. sales are down 5% YTD to $10.3 billion. Western Europe sales are up 3% and 4% for the quarter and YTD respectively, to $2.1 billion and $6.8 billion. Established rest-of-world sales are up 5%/7% to $1.3 billion and $3.7 billion, and emerging rest-of-world sales were up 14%/16% to $1.3 billion and $3.9 billion, respectively. Worldwide Crestor sales were up 20% to $1.4 billion for the quarter, and up 23% YTD to $4.1 billion. Arimidex sales plummeted 38% in 3Q10 to $284 million.